eligibility_summary
Adults ≥18 with histology/cytology-confirmed unresectable or metastatic adenocarcinoma, adequate renal, liver, and hematologic function, ECOG 0–1. Exclude significant cardiac disease, uncontrolled CNS metastases, active/known autoimmune disease, ≥Grade 3 mAb allergy, incomplete recovery from major surgery/trauma, HIV, active HBV/HCV, or pregnancy/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05808634: Phase 1, open-label, single-arm study of BA3182 in adults with advanced/metastatic adenocarcinoma. Intervention: BA3182, a conditionally active biologic (CAB) bispecific T‑cell engager antibody. Mechanism of action: simultaneously binds EpCAM on epithelial tumor cells and CD3 on T cells, redirecting and activating cytotoxic T cells to kill EpCAM-expressing cancer cells. Targets/cells/pathways: EpCAM-positive tumor cells and CD3 on T lymphocytes, engages TCR/CD3 signaling, immune synapse formation, T‑cell–mediated cytotoxicity and apoptosis, with conditional activation intended to focus activity within the tumor microenvironment.